Compare BLCO & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLCO | CZR |
|---|---|---|
| Founded | 1853 | 1937 |
| Country | Canada | United States |
| Employees | N/A | 15500 |
| Industry | Ophthalmic Goods | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 2022 | 2015 |
| Metric | BLCO | CZR |
|---|---|---|
| Price | $17.25 | $29.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $18.45 | ★ $31.92 |
| AVG Volume (30 Days) | 380.8K | ★ 3.0M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,101,000,000.00 | $1,473,504,000.00 |
| Revenue This Year | $8.65 | $3.56 |
| Revenue Next Year | $5.59 | $2.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.47 | ★ 65.03 |
| 52 Week Low | $13.77 | $17.86 |
| 52 Week High | $18.92 | $30.88 |
| Indicator | BLCO | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 47.24 |
| Support Level | $16.26 | $29.57 |
| Resistance Level | $17.78 | $30.86 |
| Average True Range (ATR) | 0.42 | 0.08 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 48.20 | 35.14 |
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.